.png){kind=logo}
The Science Behind Our Work
Research is clarifying the impacts and healing mechanisms of ketamine and other psychedelic compounds.
Journal articles
Trusted journals are publishing outcomes that demonstrate the safety and efficacy of ketamine.
Am J Psychiatry, 2016
Ketamine, an N-methyl-D-aspartate glutamate receptor antagonist, has demonstrated a rapid-onset antidepressant effect in patients with treatment-resistant depression.
Am J Psychiatry, 2013
Shows ketamine displays rapid antidepressant effects and NDMA receptor modulation as a novel mechanism for chronic depression.
J Affect Disord, 2019
Finds no serious drug-related adverse events or increased ketamine craving or abuse post-administration after single dose.
JAMA Psychiatry, 2014
Shows evidence of rapid reduction in symptom severity following ketamine infusion in patients with chronic PTSD and depression with no persistent dissociative symptoms.
Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight
Lancet Psychiatry, 2017
Concludes ketamine for treatment-resistant depression is in line with ethical principles and clinicians must ensure to follow good practices.
Research institutions
Leading research centers are exploring the potential of psychedelic medicines to address mental health conditions and more.
In 2000, the research group at the Center for Psychedelic & Consciousness Research was the first to be awarded regulatory approval to reinitiate psychedelic research after a nearly 30-year federal research ban. Their seminal work focuses on the impact of psychedelics on behavior, mood, cognition, brain function and biological health markers.
The Centre of Psychedelic Research focuses on the use of psychedelics for the treatment of mental health conditions and as a means of exploring the basis of consciousness. The Centre also aims to become a prototype for the licensed psychedelic care facilities of the future.
The Center for Psychedelic Research is part of the NYU Langone’s Department of Psychiatry. Researchers conduct and support high-quality, health-focused research to realize the clinical potential of psychedelic compounds and related drugs.
MAPS is a non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics. The organization is largely responsible for the progress of MDMA through FDA clinical trials.
Further research
Several additional universities are undertaking psychedelic research projects outside of formal psychedelic research centers.
These include, but are not limited to:
Harvard University
Yale University
Stanford University
Northwestern University
University of Chicago
Columbia University
University of Michigan
University of Wisconsin, Madison
Emory University
University of California, Berkley
University of California, Los Angeles